The new behemoth in the semiconductor industry: Avago to buy Broadcom

Avago Technologies Limited (AVGO): market cap (as of 25/09/2015): $34.2bn. Broadcom Corp. (BRCM): market cap (as of 25/09/2015): $31.4bn. Introduction Following a wave of consolidation in the semiconductor industry, which culminated last March with the NPX/Freescale $11.8bn deal, on May 27, Avago Technologies Limited and Broadcom Corporation announced that they have entered Read more…

Valeant, the serial pharma dealmaker cuts again

Valeant Pharmaceuticals International, Inc.; market cap (as of 26/02/2015): US$76.68bn Salix Pharmaceuticals, Ltd.; market cap (as of 26/02/2015): US$10.07bn     Introduction The pharmaceutical industry has undergone an intense period of consolidation in the past 18 months which is far from over as the big players take advantage of the Read more…

Pfizer sets sail for a new (nearer) shore: Hospira

Pfizer Inc.; market cap (as of 20/02/2015): US$217.75bn Hospira Inc.; market cap (as of 20/02/2015): US$14.97bn Introduction On February 5th, 2014, pharmaceutical behemoth Pfizer signed with Hospira, the world’s leading provider of injectable drugs and biosimilars, a definitive merger agreement which consists of the fully acquisition of Hospira for US$90 Read more…

AMCOL deal update: Minerals Technologies tops Imerys’ bid

AMCOL International Corporation Market Cap (as of 14/03/2014): $1.49bn Minerals Technologies Inc. Market Cap (as of 14/03/2014): $1.98bn Imerys S.A. Market Cap (as of 14/03/2014): €4.76bn On March 10th, 2014 Minerals Technologies Inc., a global developer and maker of mineral-based products, announced it has signed a definitive merger agreement with Read more…

Actavis and Forest Laboratories are going to create a long-term powerful “engine”

Actavis Plc, Market Cap (as of 21/02/14): $38.35bn Forest Laboratories Inc, Market Cap (as of 21/02/14): $26.36bn On February 18th, 2014 the Dublin-based generic drug maker, Actavis PLC, announced an acquisition of the New York-based specialty drug maker, Forest Laboratories Inc, in a $25bn cash-and-equity deal. If successfully completed, the Read more…